Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,127 stopped studies mapped to Secondary Malignant Neoplasm and descendants · 91% state a reason
Over the 2,127 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04895748 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in… | Phase 1 | terminated | May 20, 2021 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT05554354 | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in… | Phase 2 | terminated | Sep 26, 2022 | National Cancer Institute (NCI) | Other - slow accrual | Enrollment / accrual |
| NCT05676463 | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | Phase 2 | terminated | Jan 9, 2023 | Thomas Jefferson University | Loss of required MRI resources needed to conduct protocol-specified procedures | Other (stated, no rule matched) |
| NCT03211988 | Entinostat Neuroendocrine (NE) Tumor | Phase 2 | terminated | Jul 11, 2017 | Antonio Fojo | Lack of funding and drug supply | Drug supply |
| NCT05296135 | Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer(PREDAPT-HNSCC2) | — | withdrawn | Mar 25, 2022 | Cofactor Genomics, Inc. | No patients were recruited or enrolled in this study. | Enrollment / accrual |
| NCT03801369 | AMTEC IIT: Phase 2 Multiarm Study in TNBC | Phase 2 | terminated | Jan 11, 2019 | Gordon Mills, MD, PhD | loss of funding | Funding |
| NCT05159050 | Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis | Phase 1 | terminated | Dec 15, 2021 | Carlos Chan | Drug supply issues | Drug supply |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or… | Phase 1 | terminated | Oct 3, 2024 | Accent Therapeutics | The study was terminated by sponsor based on the adverse event profile. | Safety / toxicity |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary… | Phase 2 | terminated | Dec 24, 2018 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | Phase 1 / Phase 2 | withdrawn | Oct 4, 2022 | Intima Bioscience, Inc. | No recruitment | Enrollment / accrual |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic… | Phase 1 | terminated | Feb 10, 2022 | Pfizer | Study terminated based on internal business considerations and was not based on safety reasons | Safety / toxicity |
| NCT03165721 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in… | Phase 2 | terminated | May 24, 2017 | National Cancer Institute (NCI) | Study closed to enrollment due to low accrual. | Enrollment / accrual |
| NCT06217094 | Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 | withdrawn | Jan 22, 2024 | University of Florida | funding terminated | Funding |
| NCT06851104 | A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With… | Phase 2 | terminated | Feb 28, 2025 | Guangxi Medical University | The support from the relevant company was not obtained as planned | Sponsor / business decision |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With… | Phase 1 / Phase 2 | withdrawn | Apr 5, 2022 | Institut de Recherches Internationales Servier | Strategic development reasons | Sponsor / business decision |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination… | Phase 1 / Phase 2 | terminated | Apr 5, 2017 | M.D. Anderson Cancer Center | \<75% accrued | Enrollment / accrual |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory… | Phase 1 / Phase 2 | terminated | Nov 12, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06585969 | A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal…(DISCORDANT) | Phase 3 | withdrawn | Sep 19, 2024 | Danish Breast Cancer Cooperative Group | Lack of funding | Funding |
| NCT05928806 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial(ARCITECT) | Phase 2 | suspended | Jul 3, 2023 | Michael B. Atkins, MD | Interim Analysis | Efficacy / futility |
| NCT03875144 | Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)(MESOTIP) | Phase 2 | suspended | Mar 14, 2019 | Institut du Cancer de Montpellier - Val d'Aurelle | This decision was taken following the occurrence of three cases of serious and unexpected suspected… | Safety / toxicity |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT06716853 | A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With…(TEM-GU) | Phase 1 / Phase 2 | terminated | Dec 4, 2024 | Genenta Science | Persistent challenges have been encountered in patient recruitment, difficulty in identifying a… | Safety / toxicity |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Feb 15, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05489250 | The PLATON Network(PLATON) | — | terminated | Aug 5, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sponsor Decision | Sponsor / business decision |
| NCT06939036 | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )(SANTANA-225) | Phase 1 / Phase 2 | terminated | Apr 22, 2025 | Ariceum Therapeutics GmbH | Study terminated due to strategic business decisions. | Sponsor / business decision |
| NCT04913220 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With… | Phase 1 / Phase 2 | terminated | Jun 4, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High… | N/A | withdrawn | Nov 10, 2025 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT04258566 | Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies | N/A | terminated | Feb 6, 2020 | National Institutes of Health Clinical Center (CC) | Recruitment difficulty | Enrollment / accrual |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 19, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT02381548 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Mar 6, 2015 | National Cancer Institute (NCI) | Other - Adverse Events | Safety / toxicity |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant…(Spencer) | Phase 1 / Phase 2 | terminated | Dec 5, 2019 | Enterome | Strategic decision | Sponsor / business decision |
| NCT05814666 | Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC(PEMDA-HN) | Phase 2 | terminated | Apr 18, 2023 | Flamingo Therapeutics NV | Interim analysis was negative | Efficacy / futility |
| NCT06290856 | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced… | — | terminated | Mar 4, 2024 | Oslo University Hospital | The platform used for detecting ctDNA was not sensitive enough. | Other (stated, no rule matched) |
| NCT05014698 | IDEntification of New Predisposition Genes in Differentiated THYroid Cancer(IDENTHY-K) | N/A | terminated | Aug 20, 2021 | Nantes University Hospital | end-of-study visit not completed within the protocol timeframe | Other (stated, no rule matched) |
| NCT05223647 | Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer(TRIPLEX) | Phase 3 | terminated | Feb 4, 2022 | Norwegian University of Science and Technology | Termination was adviced by Data Safety Committee due to excess toxicity of the experimental… | Safety / toxicity |
| NCT04095689 | Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple…(INTEGRAL) | Phase 2 | terminated | Sep 19, 2019 | The Methodist Hospital Research Institute | Stopping rules met per protocol, trial will be terminated | Other (stated, no rule matched) |
| NCT04163952 | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or… | Phase 1 | terminated | Nov 15, 2019 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT04862455 | NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic… | Phase 2 | terminated | Apr 28, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT05987176 | Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients…(NELMAS) | Phase 2 | terminated | Aug 14, 2023 | Imperial College London | The study has closed earlier than planned due to one of the funders decision to withdraw the… | Funding |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With…(neoMono) | Phase 2 | terminated | Feb 25, 2021 | Palleos Healthcare GmbH | The trial stopped recruitment prematurely after a first planned interim analysis of the first 100… | Efficacy / futility |
| NCT02917759 | Liver and Biliary Tumor Tissue Registry | — | terminated | Sep 28, 2016 | Mayo Clinic | Lack of funding to support enrollment | Enrollment / accrual |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations… | Phase 2 | terminated | Jun 27, 2024 | Lipomedix Pharmaceuticals Inc. | Sponsor decision | Sponsor / business decision |
| NCT01048853 | Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer | N/A | terminated | Jan 14, 2010 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT04578106 | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2…(ELPIS) | Phase 2 | terminated | Oct 8, 2020 | Fundacio Clinic Barcelona | The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize… | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 3, 2026source: clinicaltrials